- Home
- IDYA vs XENE Comparison
IDYA vs XENE Comparison
Compare IDYA & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- XENE
- Stock Information
- Founded
- IDYA 2015
- XENE 1996
- Country
- IDYA United States
- XENE Canada
- Employees
- IDYA N/A
- XENE N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- IDYA Health Care
- XENE Health Care
- Exchange
- IDYA Nasdaq
- XENE Nasdaq
- Market Cap
- IDYA 2.0B
- XENE 2.3B
- IPO Year
- IDYA 2019
- XENE 2014
- Fundamental
- Price
- IDYA $21.67
- XENE $32.05
- Analyst Decision
- IDYA Strong Buy
- XENE Strong Buy
- Analyst Count
- IDYA 12
- XENE 11
- Target Price
- IDYA $54.27
- XENE $54.82
- AVG Volume (30 Days)
- IDYA 1.2M
- XENE 991.1K
- Earning Date
- IDYA 08-05-2025
- XENE 08-07-2025
- Dividend Yield
- IDYA N/A
- XENE N/A
- EPS Growth
- IDYA N/A
- XENE N/A
- EPS
- IDYA N/A
- XENE N/A
- Revenue
- IDYA $7,000,000.00
- XENE $7,500,000.00
- Revenue This Year
- IDYA $101.20
- XENE N/A
- Revenue Next Year
- IDYA $286.70
- XENE $253.71
- P/E Ratio
- IDYA N/A
- XENE N/A
- Revenue Growth
- IDYA N/A
- XENE N/A
- 52 Week Low
- IDYA $13.45
- XENE $26.74
- 52 Week High
- IDYA $44.42
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- IDYA 58.21
- XENE 51.34
- Support Level
- IDYA $21.09
- XENE $31.22
- Resistance Level
- IDYA $22.50
- XENE $33.46
- Average True Range (ATR)
- IDYA 0.97
- XENE 1.28
- MACD
- IDYA -0.04
- XENE 0.27
- Stochastic Oscillator
- IDYA 56.44
- XENE 68.60
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.